CapWealth Advisors LLC Acquires 1,721 Shares of Gilead Sciences (GILD)

CapWealth Advisors LLC increased its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 151,212 shares of the biopharmaceutical company’s stock after buying an additional 1,721 shares during the period. Gilead Sciences comprises approximately 1.9% of CapWealth Advisors LLC’s portfolio, making the stock its 20th largest position. CapWealth Advisors LLC’s holdings in Gilead Sciences were worth $10,833,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Welch Investments LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $144,000. Hanson & Doremus Investment Management lifted its position in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the period. Finally, Rational Advisors LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $170,000. Institutional investors and hedge funds own 78.35% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other Gilead Sciences news, Director Gayle E. Wilson sold 60,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the sale, the director now owns 182,258 shares in the company, valued at approximately $14,201,543.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the sale, the chairman now owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. Insiders have sold a total of 308,600 shares of company stock valued at $24,328,226 in the last 90 days. 1.30% of the stock is currently owned by company insiders.

Shares of GILD stock opened at $73.70 on Monday. The firm has a market cap of $96,093.74, a price-to-earnings ratio of 8.61, a price-to-earnings-growth ratio of -1.67 and a beta of 1.19. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. Gilead Sciences’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.70 EPS. analysts forecast that Gilead Sciences will post 6.32 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date of this dividend was Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is 26.64%.

A number of brokerages have recently issued reports on GILD. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Thursday. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Tuesday, April 17th. Barclays restated an “overweight” rating and issued a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Finally, Royal Bank of Canada restated a “buy” rating and issued a $94.00 price target on shares of Gilead Sciences in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $88.65.

ILLEGAL ACTIVITY NOTICE: “CapWealth Advisors LLC Acquires 1,721 Shares of Gilead Sciences (GILD)” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/04/23/capwealth-advisors-llc-acquires-1721-shares-of-gilead-sciences-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply